Clinical Research Directory

Inclusion Criteria: * HIV-1 infected, 18 years or older * On stable \& suppressive triple cART for at least 6 months * No evidence of resistance to DOR or DTG * No laboratory abnormalities, medical/psychiatric conditions or alcohol/drug use considered a barrier to participation by investigators * Women who are pre-menopausal and sexually active should be on one of the following methods of contraception: * Implant * Depot injection * Intra-uterine device or system * Oral hormonal contraception Exclusion Criteria: * History of virological failure on an NNRTI in absence of a post-failure genotypic resistance test proving absence of resistance to DOR * History of virological failure on an INSTI in absence of a post-failure genotypic resistance test proving absence of resistance to DTG (INSTI mutations that will lead to the need of administering DTG twice-daily are considered as resistance to DTG - and the subject will be considered NOT eligible) * Concomitant medication contra-indicated with DTG or DOR * Haemoglobin \<9 g/dL * Platelets \<80,000/mm3 * Creatinine clearance \<30 mL/min * AST or ALT ≥5N * Acute Hepatitis A infection. * Concomitant DAA for anti-HCV therapy * Known acute or chronic viral hepatitis B or C. * Individuals testing positive for HBcAb, but negative HBsAg/HBeAg, may be included on the trial. * Individuals with positive anti-HCV results, but with HCV RNA not detected may be included on the trial. * Pregnant or breastfeeding women